You just read:

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Oct 19, 2010, 08:15 ET